The possibility of an additional condition resulting in a cancer predisposition was evaluated using germline Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT), which analyzed 90 cancer predisposition genes, as well as dedicated testing for Beckwith–Wiedemann syndrome (BWS), including methylation and copy number analysis of 11p15.5 and CDKN1C sequencing. This evidence concerns the gene CDKN1C and cancer.